Patent Baristas

In a session on Case Law Updates at the the BIO Intellectual Property Counsel Committee’s Fall Conference and Committee Meeting, Chad Shear led a panel discussion with John Dragseth and Dr. John Garvish through a discussion of Bilski and how we got to Bilski.  The case, involved a patent application seeking exclusive rights to a […]

Editor-in-Chief Barista, Stephen Jenei, will be live-blogging the BIO Intellectual Property Counsel Committee’s Fall Conference and Committee Meeting on Oct. 20-22, 2008, at the Hard Rock Hotel at Universal Orlando, Orlando, Florida. The Conference should be an excellent opportunity for BIO members to hear, listen, and learn about current and projected topics related to biotechnology […]

It’s a well-known fact that drug industries pursue patents with a zeal that few possess – after all, a patent in the hand is worth millions in the bank and a relative monopoly over the pharmaceutical market. They lobby for political support to push these patents through, even if they know that the drugs have […]

There has been a lot of activity at the Supreme Court and at the PTO in the last year. The increase in litigation increases the cost of pursuing patents and the serious pitfalls companies will face if they are not careful. It doesn’t take the Amazing Kreskin to realize that the PTO is rejecting a […]

Pointing out that Senators Obama and McCain agree on the need for affordable biologic medicines, Biologicsland now offers a game for testing your knowledge about biogenerics. Biologicsland, brought to you by Teva Pharmaceuticals, is an on-line board game where you pick a person to act as your player, like politician or scientist (and why is […]

Noting that the KSR v. Teleflex decision had immediate effect of making patents more difficult to obtain — allowances of patent applications declined 43% in the first quarter of this year alone — Robert Yeager of the law firm K&L Gates LLP discusses these matters in a recently published “Legal Backgrounder” by the Washington Legal […]

With billions of dollars at stake as global business practices are scrutinized in the United States, the EU, and Asia, the challenges and consequences could not be greater for high-tech companies. The competition issues raised require detailed analysis of fast-moving areas of technology, such as the Internet, computer software and hardware, platform competition and technology […]

After the district court held that an earlier patent (Pat. No. 5,236,940) did not qualify as an enabling prior art reference and didn’t anticipate claims of U.S. Pat. No. 5,527,814, relating to the use of riluzole to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), the U.S. Court of Appeals for the Federal Circuit […]